Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|November 13, 2009

Diabetes & Obesity Podcasts: Obesity Drugs and Co-Morbidities

Diabetes & Obesity Series


Obesity Drugs and Co-Morbidities

Subscribe to RSS feed of this series



Dr. Richard Gregg
Chief Scientific Officer
Vitae Pharmaceuticals



Dr. Gregg offers insight into the development of obesity drugs, and how co-morbidities factor into development, as well as how it impacts sites and CROs in Phase I through III trials.

Others in the Series




Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.